Inhixa

Enoxaparin Sodium, the active ingredient in Inhixa, is a low molecular weight heparin presented as an injectable solution for subcutaneous, intravenous, or hemodialysis use. It is employed to prevent and treat thromboembolic conditions in adult patients at risk of clot formation. GNH USA supplies Inhixa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Enoxaparin Sodium is a low molecular weight heparin used to prevent and treat thromboembolic disorders.

- Deep vein thrombosis (DVT) prevention: reduces the risk of clot formation in surgical or immobilised patients. - Pulmonary embolism (PE) treatment: facilitates clot resolution and prevents recurrence. - Anticoagulation during hemodialysis: maintains circuit patency by inhibiting clotting during the procedure.

Enoxaparin Sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site pain or bruising: local irritation at the administration site. - Minor bleeding: epistaxis, gum bleeding, or easy bruising. - Nausea or vomiting: gastrointestinal discomfort. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness. - Elevated liver enzymes: mild, transient changes in hepatic labs.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening internal bleeding. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop. - Spinal or epidural hematoma: bleeding in the central nervous system after neuraxial procedures. - Severe allergic reaction: anaphylaxis or angioedema. - Disseminated intravascular coagulation (DIC): uncontrolled clotting and bleeding. - Acute renal failure: rare kidney impairment associated with high doses.

When using Enoxaparin Sodium, clinicians should observe several safety measures.

- Renal impairment: assess kidney function and adjust dose as needed. - Surgery or invasive procedures: discontinue before to minimise bleeding risk. - Concomitant anticoagulants or antiplatelet agents: monitor closely for additive bleeding. - Pregnancy and lactation: use only if the benefit outweighs potential risk. - Platelet monitoring: check for thrombocytopenia indicative of HIT. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin Sodium can interact with several drug classes, affecting bleeding risk or anticoagulant effect.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): markedly increase bleeding. - Antiplatelet agents (aspirin, clopidogrel, ticagrelor): additive hemorrhagic risk. - Fibrinolytic therapy (tPA, streptokinase): potentiate bleeding complications. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): enhance mucosal bleeding. - Neuraxial anesthesia or spinal puncture: risk of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely): - Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide): may increase anticoagulant effect. - Certain antibiotics (e.g., penicillins, cephalosporins): can alter anti‑Xa activity. - Hormonal therapies (estrogen, oral contraceptives): modestly raise thrombosis risk.